Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

Area of Science:

• Oncology
• Pharmacology

Background:

• Cetuximab dosing every 2 weeks (Q2W) is approved for metastatic colorectal cancer and head and neck squamous cell carcinoma.
• Phase II trials and real-world studies indicate comparable efficacy and safety between weekly (Q1W) and Q2W cetuximab schedules.

Purpose of the Study:

• To evaluate the noninferiority of the cetuximab Q2W schedule compared to the Q1W schedule.
• To highlight the convenience and potential benefits of the Q2W dosing schedule.

Main Methods:

• Review of Phase II trial data.
• Analysis of real-world studies comparing Q1W and Q2W cetuximab administration.

Main Results:

• Real-world studies demonstrated noninferiority of the Q2W schedule versus the Q1W schedule.
• The Q2W schedule allows for concurrent administration with Q2W chemotherapy, enhancing convenience.

Conclusions:

• Cetuximab Q2W is a recommended alternative to Q1W dosing.
• The Q2W schedule offers potential advantages including reduced administration costs, increased staff flexibility, and improved patient adherence.